Ann: Unusual Trading Patterns, page-210

So Eire why dont the big strategics with their m&a groups see this as bargain of the century. Some of these big medtech has free cashflows of running into the billions so picking this up is short change I’ve seen many promising medtech acquired very short into commerialization Personally if i was doing due diligence on this company fact that management not having any skin in the game would set my alarm bells ringing with big salaries, also track record over past few years is very poor so getting in new leader with tracker record in interventional cardiology exit would be a great start., I suspect they will need to clear regulatory approval by fda before everything becomes meaningful and recognized.